RxDoctor Payments Data

Lauren Barfield, MD

Internal Medicine · Baton Rouge, LANPI 1437341252

Payments from drug & device makers

$13,008in general payments, 2019–2025

Across 820 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • GSK$1K
  • Pfizer$816
  • Amgen$713
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$12,986100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,008 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$67,354
Medicare patients
212
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin187$220,660
MounjaroTirzepatide118$155,632
OzempicSemaglutide75$109,187
TrulicityDulaglutide38$60,440
LinzessLinaclotide59$47,563
EliquisApixaban55$41,862
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$41,411
XareltoRivaroxaban35$38,930
RybelsusSemaglutide24$26,123
FarxigaDapagliflozin Propanediol19$25,850
MyrbetriqMirabegron40$25,159
GemtesaVibegron39$24,569
VascepaIcosapent Ethyl33$20,645
WegovySemaglutide11$19,782
EntrestoSacubitril/Valsartan20$16,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$1,494$235,493206 claims
Lilly USA, LLCMounjaro, Trulicity$1,303$216,072156 claims
Novo NordiskOzempic, Rybelsus, Wegovy$1,302$155,092110 claims
AbbVieLinzess, Synthroid$643$49,59292 claims
PfizerEliquis$816$41,86255 claims
GSKTrelegy Ellipta$1,004$41,41151 claims
Johnson & JohnsonXarelto$436$38,93035 claims
AstraZenecaFarxiga, Symbicort$662$31,93833 claims
Astellas Pharma US IncMyrbetriq$533$25,15940 claims
Sumitomo Pharma America, Inc.Gemtesa$413$24,56939 claims
NovartisEntresto$406$16,42720 claims
MerckJanuvia$596$10,40923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →